6 results about "Insulin deficiency" patented technology

The application relates to an induced type 2 diabetes mellitus feed and application thereof in establishing a type 2 diabetes mellitus animal model, and relates to the field of experimental animal models, and particularly relates to an induced type 2 diabetes mellitus feed and application thereof in establishing a type 2 diabetes mellitus animal model. The application aims at solving the problems of long modeling time, instability and easy change into a type 1 diabetes mellitus model of the existing type 2 diabetes mellitus animal model establishing method. The feed comprises desulfurization vibrio powder, symbiotic clostridium powder and high-fat high-sugar feed. The method comprises the following steps: drying desulfurization vibrio liquid and symbiotic clostridium liquid into powder, uniformly mixing the powder and the high-fat high-sugar feed, and extruding into a column shape by using an extrusion molding machine. The application significantly shortens the establishment time of the type 2 diabetes mellitus animal model, does not need to inject a high-dose STZ, and does not cause the type 1 diabetes mellitus model of absolute insulin deficiency of rats in the case of using a higher concentration of STZ induction. The induced type 2 diabetes mellitus feed is used for establishing the type 2 diabetes mellitus animal model.

The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.

The present disclosure provides compositions of stem cell-derived pancreatic islet cells engineered for improved engraftment and methods of use thereof for treating a subject having an insulin deficiency.

This disclosure provides cell-based compositions for the treatment of diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for the treatment of insulin deficiency-related diseases.

Systems comprising: an analyte sensor for providing an analyte signal representative of an analyte level; a controller in data communication with the analyte sensor and programmed to provide a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and a model-based safety mechanism integrated with the controller for evaluating the recommended medication dose. Wherein the model-based safety mechanism overrides the recommended medication dose and provides a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.